Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,294.9
0.0 (0.00%)

 

  • STI Straits Times Index
    3,294.9
    0.0 (0.00%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,527.1
    -0.7 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,965.5
    13.2 (0.05%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,522.6
    -32.5 (-0.91%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 805.0M
  • Value: 1,097.8M
  • Rise: 135
  • Fall: 158
  • Unch: 474

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.086+0.003
DISA0.009+0.001
ThaiBev0.660+0.005
The Place Hldg0.074+0.016
Geo Energy Res0.355+0.025
Sembcorp Marine0.083-
Arion Ent0.011+0.001
Singtel2.480+0.010
Oceanus0.029+0.001
Genting Sing0.775-0.005

World Indices

World Indices
Name Last Change
Nasdaq 13,768.9 -385.1
HSI 24,965.5 +13.2
HSCEI 8,787.3 +25.7
Jakarta 6,726.4 +99.5
Nikkei 225 27,522.3 -250.7
SSE Comp 3,522.6 -32.5
Shanghai A 3,691.5 -34.1
Shanghai B 286.2 -0.8
KOSPI 2,834.3 -28.4

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

PFIZER INC PFIZER INC
Updated on 21 Jan 2022 (End of trading day)
Last (USD): 52.790 Change: -1.260 High: 54.865 Remarks: -
Change (%): -2.33 Low: 52.464
Open 54.420 Yesterday's Close 54.05
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 40,973,970 Cumulative Value

Company Background

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a 1.71321 Trailing EPS (USD) b 3.41715 NAV (USD) c 13.4851
PE a 30.814 Trailing PE d 15.449 Price / NAV c 3.9147
Dividend Yield (%) e 2.875 Cash In Hand (USD) f 0.3503 Issued & Paid-up Shares g 5,612,870,000
Piotroski F Score 4 Market Cap (M) 296,303.407 Free Float (%) -
Return on Equity (ROE) (%) h 25.340 Revenue Growth (%) TTM i n.a.
Net Earnings Growth (%) j n.a. Net Debt/Equity k 0.135
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 22 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --2.160
-3.93 %
10 Days --2.930
-5.26 %
20 Days --5.920
-10.08 %
Medium Term Return 3 Months 0.390+9.630
+23.22 %
6 Months 0.780+11.110
+28.53 %
1 Year 1.560+16.240
+48.70 %
Long Term Return 2 Years 3.080+12.970
+40.31 %
3 Years 4.520+12.150
+41.02 %
5 Years 7.160+21.370
+90.80 %
Annualised Return Annualised --
+13.79 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference PFIZER INC NYSE 296,303.407 30.814 15.449 3.9147 2.875
Industry Pharmaceuticals: Major NYSE 117,649.075 35.556 26.503 5.6321 1.925
Local Peer JOHNSON & JOHNSON NYSE 434,036.762 29.498 24.275 6.1765 2.414
Local Peer ABBVIE INC NYSE 233,324.802 51.213 31.294 17.2196 3.662
Local Peer ELI LILLY AND COMPANY NYSE 232,509.252 37.540 38.931 29.9741 1.218
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 211,867.573 26.247 21.604 3.7320 2.215
Local Peer MERCK & CO INC NYSE 202,024.681 28.587 28.071 5.6441 3.106
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 169,031.322 26.231 22.771 16.4043 1.411
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 141,036.561 - - 3.7900 2.928
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 113,467.090 15.391 19.122 5.4552 4.588
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 46,391.717 13.085 10.501 0.9722 5.226
Local Peer ORGANON & CO NYSE 7,852.444 3.635 5.176 -4.8532 -
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 7,592.229 - - -12.9125 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,526.925 8.282 11.132 1.6595 -
Other Local Peers AMNEAL PHARMACEUTICALS INC (NYSE), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), ANNOVIS BIO INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,139.080 57.302 124.500 4.6080 1.964
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 129,489.629 9.224 18.699 1.7267 -
Global Peer WUXI APPTEC CO LTD HKEx 359,491.010 108.314 72.361 7.9831 0.289
Global Peer ROYALTY PHARMA PLC NASDAQ 23,764.790 24.373 30.358 4.1023 0.490
Global Peer VIATRIS INC NASDAQ 17,572.437 - - 0.8312 -
Global Peer HANSOH PHARMACEUTICAL GROUP CO LTD HKEx 110,866.392 38.406 35.879 4.9280 0.412
Global Peer REPLIGEN CORP NASDAQ 10,162.579 169.585 85.487 5.9248 -
Global Peer INNOVENT BIOLOGICS INC HKEx 61,116.198 - - 4.2713 -
Global Peer SINOPHARM GROUP CO. LTD. HKEx 58,106.689 7.195 6.309 0.8366 4.508
Global Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 6,998.939 981.791 23.759 6.0836 -
Other Global Peers SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CANSINO BIOLOGICS INC (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), OPKO HEALTH INC (NASDAQ), GRAND PHARMACEUTICAL GROUP LTD (HKEx), AKESO INC (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), EQRX INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE PHARMA LTD (HKEx), IMMUNITYBIO INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), CLOVER BIOPHARMACEUTICALS LTD (HKEx), SHANGHAI HENLIUS BIOTECH INC (HKEx), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), SSY GROUP LIMITED (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), ERASCA INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), EVEREST MEDICINES LTD (HKEx), OCUMENSION THERAPEUTICS (HKEx), AMYLYX PHARMACEUTICALS INC (NASDAQ), CSTONE PHARMACEUTICALS (HKEx), UNITED LABORATORIES INTL HLDGS LTD (HKEx), KEROS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), QUANTERIX CORPORATION (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), Kimia Farma Tbk. (IDX), GH RESEARCH PLC (NASDAQ), GOSSAMER BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CHINOOK THERAPEUTICS INC (NASDAQ), ABBISKO CAYMAN LTD (HKEx), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), ANTENGENE CORP LTD (HKEx), PRAXIS PRECISION MEDICINES INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), IGM BIOSCIENCES INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), Soho Global Health Tbk. (IDX), PHARVARIS NV (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ICOSAVAX INC (NASDAQ), CINCOR PHARMA INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), KRONOS BIO INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), TRICIDA INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE (HKEx), OCULAR THERAPEUTIX INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), VERU INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), IGBB (Bursa), CANBRIDGE PHARMACEUTICALS INC (HKEx), TALARIS THERAPEUTICS INC (NASDAQ), ALLAKOS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), GENERATION BIO CO (NASDAQ), GRITSTONE BIO INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), ESSA PHARMA INC (NASDAQ), RACE ONCOLOGY LTD (ASX), OYSTER POINT PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), AC IMMUNE SA (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), ANNEXON INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), EYEPOINT PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), LIQUIDIA CORPORATION (NASDAQ), IMMUNIC INC (NASDAQ), EVOLUS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), BSTEAD (Bursa), OLEMA PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), MILESTONE PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), 89BIO INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), GENENTA SCIENCE SPA SPON ADS EACH REP 1 ORD SHS (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), IP (SET), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CLENE INC (NASDAQ), CYBIN INC (NYSE American), SOL GEL TECHNOLOGIES LTD (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), DURECT CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), INOZYME PHARMA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), OBSEVA SA (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ALZAMEND NEURO INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), TCR2 THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), MUSTANG BIO INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), CLEARSIDE BIOMEDICAL INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), KOTRA (Bursa), ATHENEX INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), IX Biopharma (SGX), MINK THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), JP (SET), ONCTERNAL THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), INVION LTD (ASX), EYENOVIA INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), POLYPID LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), NOXOPHARM LTD (ASX), F-STAR THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), NOVA (Bursa), ENTERA BIO LTD (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), MANNATECH INC (NASDAQ), MEDIWOUND LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), Hyphens Pharma (SGX), Phapros Tbk. (IDX), ANGION BIOMEDICA CORP (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), ALLARITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), NOVAN INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), BIOFRONTERA INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), PAK FAH YEOW INTERNATIONAL (HKEx), GALECTO INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), NEUBASE THERAPEUTICS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), EXOPHARM LTD (ASX), BIOHLDG (Bursa), APREA THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), IMARA INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), ACURX PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), PURAPHARM CORPORATION LIMITED (HKEx), PHARMAXIS (ASX), APTORUM GROUP LIMITED (NASDAQ), IMMIX BIOPHARMA INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), AILERON THERAPEUTICS INC (NASDAQ), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), RENOVORX INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), PALLA PHARMA LTD (ASX), THE HYDRATION PHARMACEUTICALS LTD (ASX), JCT (SET), VIRPAX PHARMA INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), GRAYBUG VISION INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), CINGULATE INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), XORTX THERAPEUTICS INC (NASDAQ), IMMURON LIMITED (ASX), PANBELA THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TISSUE REPAIR LTD (ASX), ACRUX (ASX), SEQLL INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), ARIDIS PHARMACEUTICAL INC (NASDAQ), SCISPARC LTD (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), BIOME AUSTRALIA LT (ASX), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), ISLAND PHARMACEUTICALS LTD (ASX), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), DERMATA THERAPEUTICS INC (NASDAQ), AROVELLA THERAPEUTICS LTD (ASX), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), TALI DIGITAL LIMITED (ASX), FIJI KAVA LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), FARMAFORCE LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

More Information Available

More information is available to our subscribers, including:

  • Consensus Estimates
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.